AR073505A1 - Composiciones y metodos para el tratamiento de enfermedades proliferativas - Google Patents

Composiciones y metodos para el tratamiento de enfermedades proliferativas

Info

Publication number
AR073505A1
AR073505A1 ARP090103475A ARP090103475A AR073505A1 AR 073505 A1 AR073505 A1 AR 073505A1 AR P090103475 A ARP090103475 A AR P090103475A AR P090103475 A ARP090103475 A AR P090103475A AR 073505 A1 AR073505 A1 AR 073505A1
Authority
AR
Argentina
Prior art keywords
inhibitor
methods
compositions
compound
composition according
Prior art date
Application number
ARP090103475A
Other languages
English (en)
Inventor
Ernesto Jorge Podesta
Original Assignee
Monte Verde S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monte Verde S A filed Critical Monte Verde S A
Priority to ARP090103475A priority Critical patent/AR073505A1/es
Priority to US13/394,776 priority patent/US20120178782A1/en
Priority to MX2012002690A priority patent/MX2012002690A/es
Priority to PCT/BR2010/000300 priority patent/WO2011029168A1/pt
Publication of AR073505A1 publication Critical patent/AR073505A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones sinérgicas y métodos para la prevencion y el tratamiento de enfermedades proliferativas, tales como cáncer y psoriasis. Más específicamente, esta solicitud se refiere a composiciones sinérgicas y métodos para inhibir la proliferacion de células de cáncer, particularmente células de cáncer de mama y colon. Las composiciones comprenden combinaciones sinérgicas de: i) un compuesto inhibidor de la enzima Acyl-Co-A sintetasa (acsI4), ii) un compuesto inhibidor de enzimas con actividad cicloxigenasa (COX), y iii) un compuesto seleccionado de un inhibidor de la enzima 5-lipoxigenasa (LOX-5) y un compuesto antagonista de receptores de y leucotrienos. Reivindicacion 5: La composicion de acuerdo con la reivindicacion 4 caracterizada porque el inhibidor de Acsl4 se selecciona de troglitazona y rosiglitazona, sales, hidratos y solvatos de los mismos. Reivindicacion 7: La composicion de acuerdo con la reivindicacion 5, caracterizada porque el inhibidor de COX se selecciona de ibuprofeno y etoricoxib. Reivindicacion 8: La composicion de acuerdo con cualquiera de las reivindicaciones 1 o 2, caracterizada porque el inhibidor de LOX-5 se selecciona de AA861 y zileuton.
ARP090103475A 2009-09-10 2009-09-10 Composiciones y metodos para el tratamiento de enfermedades proliferativas AR073505A1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ARP090103475A AR073505A1 (es) 2009-09-10 2009-09-10 Composiciones y metodos para el tratamiento de enfermedades proliferativas
US13/394,776 US20120178782A1 (en) 2009-09-10 2010-09-10 Compositions and methods for treating proliferative diseases
MX2012002690A MX2012002690A (es) 2009-09-10 2010-09-10 Composiciones y metodos para el tratamiento de enfermedades proliferativas.
PCT/BR2010/000300 WO2011029168A1 (pt) 2009-09-10 2010-09-10 Composições e métodos para o tratamento de doenças proliferativas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP090103475A AR073505A1 (es) 2009-09-10 2009-09-10 Composiciones y metodos para el tratamiento de enfermedades proliferativas

Publications (1)

Publication Number Publication Date
AR073505A1 true AR073505A1 (es) 2010-11-10

Family

ID=43566739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103475A AR073505A1 (es) 2009-09-10 2009-09-10 Composiciones y metodos para el tratamiento de enfermedades proliferativas

Country Status (4)

Country Link
US (1) US20120178782A1 (es)
AR (1) AR073505A1 (es)
MX (1) MX2012002690A (es)
WO (1) WO2011029168A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019109147A1 (en) * 2017-12-06 2019-06-13 Omara Stephen Kenneth Methods of treating cancer with leukotriene receptor antagonists
EP3643305A1 (en) * 2018-10-25 2020-04-29 Universität für Bodenkultur Wien Compositions for the elimination of senescent cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026269A1 (en) * 1993-05-10 1994-11-24 Sepracor, Inc. Methods and compositions for treating asthma, atherosclerosis andinflammatory diseases using optically pure (-)-zileuton
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
JP2004507241A (ja) * 2000-08-21 2004-03-11 ユニバーシティ　オブ　ユタ　リサーチ　ファウンデーション ヒト脂肪酸−ＣｏＡリガーゼ４の阻害剤のスクリーニング方法
US6756399B2 (en) * 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
JP2007513173A (ja) * 2003-12-03 2007-05-24 スミスクライン・ビーチャム・コーポレイション ロシグリタゾンを用いる乾癬の治療

Also Published As

Publication number Publication date
US20120178782A1 (en) 2012-07-12
MX2012002690A (es) 2012-04-19
WO2011029168A1 (pt) 2011-03-17

Similar Documents

Publication Publication Date Title
CL2019002895A1 (es) Inhibidores de pd-1/pd-l1.
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
NZ730134A (en) Substituted tricyclic compounds as fgfr inhibitors
CU20160149A7 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
EA201592005A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
EA201390031A1 (ru) МОДИФИКАТОРЫ АРИЛУГЛЕВОДОРОДНОГО РЕЦЕПТОРА (AhR) В КАЧЕСТВЕ НОВЫХ ПРОТИВОРАКОВЫХ ТЕРАПЕВТИЧЕСКИХ СРЕДСТВ
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
MX359664B (es) Tratamiento de cáncer de mama.
MX2013008212A (es) Derivados de 7-azaindol.
UY36749A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
CU20100170A7 (es) Inhibidores heterocíclicos de estearoil-coa-desaturasa
DOP2014000074A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
CL2012002904A1 (es) Combinación o composición farmacéutica que comprende un inhibidor de la señalización de células y/o de la angiogénesis y un inhibidor de la quinasa aurora (aki); kit faramcéutico que la comprende; su uso en el tratamiento de enfermedades oncológicas y fibróticas; y compuestos derivados de indol y pirimidina sustituidos.
NI201400042A (es) 2 - tiopirimidinonas
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
ECSP12011837A (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa
AR073505A1 (es) Composiciones y metodos para el tratamiento de enfermedades proliferativas
IN2014DN08443A (es)
ZA201907676B (en) Enzyme composition for management of metabolic health

Legal Events

Date Code Title Description
FB Suspension of granting procedure